Trials / Completed
CompletedNCT04511676
The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (actual)
- Sponsor
- Phramongkutklao College of Medicine and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Levetiracetam (LEV) is one of second-generation antiepileptic drugs that has been used to treat partial and generalized epilepsy. LEV is eliminated from the systemic circulation by renal excretion. Therefore, patients with renal impairment may experience a reduced drug excretion and increased adverse drug reactions. Moreover, patients with end-stage renal disease who need dialysis may experience low serum LEV concentration because of drug loss via dialysis. LEV loss via dialysis can cause low serum level of LEV that insufficient for seizure control. The present study was aimed to evaluate pharmacokinetics of LEV in patients undergoing 4 hour-intermittent hemodialysis (IHD). The results of the study may benefit to determine the appropriate LEV initial dose and supplemental dose for patients undergoing IHD.
Conditions
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2019-10-10
- Completion
- 2019-10-10
- First posted
- 2020-08-13
- Last updated
- 2020-08-13
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT04511676. Inclusion in this directory is not an endorsement.